Healthy Skepticism Library
Items published during the years 1990 to 1999
There are 2218 items in the Healthy Skepticism Library that were published during the years 1990 to 1999.
Page 20 of 23 pages ‹ First < 18 19 20 21 22 > Last ›
HSL9457
Sesti LM, Miles WA.
Concerning the case of: United States v American Pharmaceutical Association and Michigan State Pharmaceutical Association, Civil No G75-558 CA5, WD Michigan
Journal Michigan Pharmacist 1991 May; 29:182-183
HSL9459
Dicello CA.
What pharmacy needs from industry to optimize pharmaceutical care
Pennsylvania Pharmacist 1991 May; 72:17-18
HSL9474
Summers KH.
Managed health's impact on pharmacy practice
US-Pharmacist 1991 May; 16:H16, H22-H24, H36
HSL9475
Davis JL, Madhavan S.
Should prescription drugs be advertised to consumers?
American Druggist 1991 May; 203:82, 84-85
HSL9476
Schwartz RM.
ASCP to Pryor: where are our discounts?
American Druggist 1991 May; 203:24, 26
HSL4180
Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR.
Publication bias in clinical research.
Lancet 1991 Apr 13; 337:(8746):867-72
HSL4262
The world according to Ernest: the ethics of marketing drugs
The Economist 1991 Apr 668
HSL4203
Lexchin J.
PAAB: a lesson in self-government.
CMAJ 1991 Apr 1; 144:(7):844-5
HSL4258
Re: the promotion of di-iodohydroxyquinolone
1991 Apr
HSL4259
Credibility and the marketing mix
1991 Apr
HSL4260
Griffin JP.
Who will fund postgraduate education after 1992?
J R Coll Physicians Lond 1991 Apr; 25:(2):128
http://www.ncbi.nlm.nih.gov/pubmed/2066922
HSL4261
Everett SE.
Lay audience response to prescription drug advertising
Journal of Advertising Research 1991 Apr-May; 31:43-49
HSL9467
Kirkpatrick MA.
Planning and executing a brown bag day
Pharmacy Times 1991 Apr; 57:90, 93, 96, 98
HSL9468
Mail order prescription drug industry origins and growth
Pharmacy Business 1991 Apr; 2:12, 21
HSL4257
Randall T.
New guidelines examine drug firm, CME relations.
JAMA 1991 Mar 20; 265:(11):1354
HSL4256
Purvis A.
Cheaper can be better
Time 1991 Mar 1835
HSL4280
Randall T.
FDA scrutinizes 'off-label' promotions
JAMA 1991 Mar 7; 266:(1):11
HSL4226
Scarpinato L.
Pharmaceutical representatives.
J Gen Intern Med 1991 Mar-Apr; 6:(2):181
HSL4255
Re: the promotion of arginine asparate
1991 Mar
HSL9436
Joughin J.
Animal pharm
Pharmaceutical and Cosmetic Review 1991 Mar-Apr; 18:28, 30
HSL9465
Blyth JS.
Pharmaceutical marketing in a new package
Pharmaceutical Executive 1991 Mar; 11:86, 88
HSL9466
Huntsinger L.
How Medicaid's new drug legislation will affect Oregon's drug use review and prudent purchasing programs Part 2
Oregon Pharmacist 1991 Mar; 39:8
HSL4209
Mick T.
Pharmaceutical funding and medical students.
JAMA 1991 Feb 6; 265:(5):659,
HSL4254
Kleinerman MJ.
The hand that feeds.
JAMA 1991 Feb 6; 265:(5):658,
HSL1774
Goodfriend TL.
Using pharmaceutical advertising in medical education.
Acad Med 1991 Feb; 66:(2):122
HSL4178
Dominguez-Soto L, Geo Gonzalez M.
Advertising, pharmaceutical industry, and dermatology.
Int J Dermatol 1991 Feb; 30:(2):149
HSL4200
Kopera H.
The pharmaceutical industry as a source of drug information.
Int J Clin Pharmacol Ther Toxicol 1991 Feb; 29:(2):45-7
HSL4252
Re: the promotion of minocycline
1991 Feb
HSL4253
Greenwood J.
Organised interests and the internal market
1991 Feb;
HSL9470
Huntsinger L.
How Medicaid's new drug legislation will affect Oregon's drug use review and prudent purchasing programs Part 1
Oregon Pharmacist 1991 Feb; 39:8
HSL4164
Gifts to physicians from industry.
JAMA. 1991 Jan 23-30; 265:(4):501
HSL4211
Moser M, Blaufox MD, Freis E, Gifford RW Jr, Kirkendall W, Langford H, Shapiro A, Sheps S.
Who really determines your patients' prescriptions?
JAMA 1991 Jan 23-30; 265:(4):498-500
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1985236&query_hl=45
HSL4215
Randall T.
Does advertising influence physicians?
JAMA 1991 Jan 23-30; 265:(4):443
HSL4216
Randall T.
Ethics of receiving gifts considered.
JAMA 1991 Jan 23-30; 265:(4):442-3
HSL4217
Randall T.
Kennedy hearings say no more free lunch--or much else--from drug firms.
JAMA 1991 Jan 23-30; 265:(4):440,
HSL4241
Weerasuriya K.
IFPMA code on advertising.
Lancet 1991 Jan 19; 337:(8734):178
HSL4204
Lexchin J.
A sample argument.
CMAJ 1991 Jan 15; 144:(2):118-9
HSL9473
Conlan MF.
Drug firms spend $165 million a year to influence prescribers
Drug Topics 1991 Jan 7; 135:44, 46, 48
HSL4250
Stern RS, Arndt KA, Baughman RB.
Consensus reports from the convinced: manipulating the information transfer process for drug promotion.
JAMA 1991 Jan 2; 265:(1):30
HSL4193
Hume AL, Shaughnessy AF.
Sources of influence on the prescribing practices of residents in family medicine.
DICP 1991 Jan; 25:(1):102-3
HSL4246
Legislation for the sake of legislation: the EC advertising proposal
Health Horizons 1991 Jan
www.ifpma.rog/hhhs/welcome.htm
HSL4247
MaLAM Letter follow up—Upjohn announce worldwide withdrawal of Kaomycin
MaLAM Newsletter 1991 Jan
HSL4248
Re: the promotion of oral streptokinase/streptodornase
1991 Jan
HSL4249
Summary of correspondence July ’89—June ’90
MaLAM Newsletter 1991 Jan
HSL9480
Leblang TR.
Expert witnesses
American Druggist 1991 Jan; 203:51
HSL9493
Summary of 1990 Medicaid drug rebate legislation: ASHP Government Affairs Division.
Am J Hosp Pharm 1991 Jan; 48:(1):114-7
HSL2109
Labossiere MC.
Fallacies: The Nizkor Project
1991
http://www.nizkor.org/features/fallacies/index.html
HSL2713
Lee PR, Lurie P, Silverman MM, Lydecker M.
Drug promotion and labeling in developing countries: an update.
J Clin Epidemiol 1991; 44:
HSL3676
Masson A.
Direct-to-consumer advertising: a continuing controversy. Proceedings of the
Snowbird Utah: Direct-to-consumer advertising: a continuing controversy. Proceedings of the 1991
HSL4165
Ahmad SR.
Crackdown on misleading drug promotion
Lancet 1991; 338:1384-1385
HSL4166
Anderson J, Felson DT, Meenan RF.
Secular changes in published clinical trials of second-line agents in rheumatoid arthritis
Arthritis and Rheumatism 1991; 34:1304-1309
HSL4167
Arkinstall WW.
Medical ethics
Annals of the Royal College of Physicians and Surgeons of Canada 1991; 24:161
HSL4168
Barrett J.
Cost-effectiveness in advertising
Lancet 1991; 338:699-700
HSL4170
Boyer JG, Hirsch JD, Osterhaus JT, Townsend RJ.
Potential for bias in economic analyses
New England Journal of Medicine 1991; 325:1385
HSL4171
Chan J, Einarson T.
Drug detailing in the hospital: background for policy development
Canadian Journal of Hospital Pharmacy 1991; 44:161-166
HSL4172
Chepesiuk R.
CE sponsorship
Drug Merchandising 1991; 72:(6):7
HSL4173
Chirac P.
Ethics in the pharmaceutical industry: acceptance of responsibility or a facet of marketing?
International Journal of Risk & Safety in Medcine 1991; 2:7-10
HSL4174
Clairman A.
Junk mail reduction
Canadian Family Physician 1991; 37:282
HSL4175
Clearwater G.
Advertising junk mail
New Zealand Medical Journal 1991; 104:344
HSL4176
Cone M.
Activities of the International Federation of Pharmaceutical Manufacturers Associations in world health.
J Clin Epidemiol 1991; 44:
HSL4177
Cutrer CM, Pleil AM.
Potential outcomes associated with direct-to-consumer advertising of prescription drugs: physicians’ perspectives
Journal of Pharmaceutical Marketing & Management 1991; 5:(3-19):
HSL4179
Donaldson MS, Capron AM.
Potential for bias in economic analyses
New England Journal of Medicine 1991; 325:1384-1385
HSL4181
Fevang L.
CPhA replies
Drug Merchandising 1991; 72:(6):7, 9
HSL4182
Garattini S.
An end to the fun and games?
Lancet 1991; 338:749-750
HSL4183
Gilgore LS.
A consideration of direct-to-consumer advertising of prescription drugs and potential legal problems with the brief summary requirement: Is the FDA's regulatory authority illusory?
Food Drug Cosmetic Law Journal 1991; 46:849-859
HSL4184
Goihman-yahr M.
Editorial comment [response to Dominguez-Soto (1991)]
International Journal of Dermatology 1991; 30:(2):149
HSL4186
Goldstein JH.
Doctoring medicine: reading between the lines of drug advertisements
Journal of Medical Humanities 1991; 12:(2):73-83
HSL4187
Hardon A, Van Der, Geerling H, Le Grand.
The provision and use of drugs in developing countries: a review of studies and annotated bibliography
1991
HSL4188
Harvey K, Mansfield P.
Drug promotion: the critical approach
Australian Prescriber 1991; 14:(1):34-35
HSL4189
Herxheimer A, Lundborg CS, Westerholm B.
Advertisements for medicines in medical journals: a collaborative international study
1991;
HSL4191
Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, Kinosian B, Schwartz JS.
Potential for bias in economic analyses
New England Journal of Medicine 1991; 325:1385
HSL4192
Hoffman JR.
A knotty ethical dilemma
Emergency Medicine News 1991; 13:(5):2, 14-15
HSL4195
Johnson JE.
Of mugs and marketing [1st of 3 letters]
JAMA 1991; 266:(20):2830
HSL4196
Kelly MJ.
Of mugs and marketing [3rd of 3 letters]
JAMA 1991; 266:(20):2830
HSL4198
Kirkland LR.
Of mugs and marketing [2nd of 3 letters]
JAMA 1991; 266:(20):2830
HSL4199
Kleinman DL, Cohen LJ.
The decontextualization of mental illness: the portrayal of work in psychiatric drug advertisements.
Soc Sci Med 1991; 32:(8):867-74
HSL4201
Krimsky S, Ennis JG, Weissman R.
Academic-corporate ties in biotechnology: a quantitative study.
Sci Technol Human Values 1991 Sum; 16:(3):275-87
HSL4202
Lee D.
Drug utilization in Panama.
J Clin Epidemiol 1991; 44:
HSL4205
Mann CC, Plummer ML.
The aspirin wars: money, medicine, and 100 years of rampant competition
1991
HSL4206
Mansfield PR.
Encouraging drug companies to be honest
Australian Prescriber 1991; 14:74
HSL4207
Mansfield PR.
Classifying improvements to drug marketing and justifications for claims of efficacy
International Journal of Risk & Safety in Medicine 1991; 2:171-184
HSL4214
Prather JE.
Decoding advertising: the role of communication studies in explaining the popularity of minor tranquillisers
1991112-135
HSL4220
Rennie D.
Of mugs and marketing [2nd of 2 replies]
JAMA 1991; 266:(20):2831
HSL4222
Riska E, Hagglund U.
Advertising for psychotropic drugs in the Nordic countries: metaphors, gender and life situations.
Soc Sci Med 1991; 32:(4):465-71
HSL4223
Rothman KJ.
The ethics of research sponsorship.
J Clin Epidemiol 1991; 44:
HSL4224
Rovers JP.
The doctor’s, the druggist’s, and the detail rep’s dance: who leads, who follows?
Canadian Family Physician 1991; 37:100-104
HSL4225
Ruby LA, Montagne M.
Direct-to-consumer advertising: a case study of the Rogaine® campaign
Journal of Pharmaceutical Marketing & Management 1991; 6:(2):21-32
HSL4229
Sibbison JB.
Prescription drug advertising to the public
Lancet 1991; 337:724
HSL4230
Skolnick AA.
FDA issues draft 'concept paper' on drug company funding of CME
JAMA 1991; 266:(21):2947-2948
HSL4231
Smith NC, Quelch JA.
Pharmaceutical marketing practices in the Third World
Journal of Business Research 1991; 23:113-126
HSL4233
Squires BP.
PAAB: a lesson in self-government
Canadian Medical Association Journal 1991; 144:844-845
HSL4234
Squires BP.
Stress and the ethical physician
Canadian Medical Association Journal 1991; 145:1081
HSL4235
Taylor RJ, Bond CM.
Change in the established prescribing habits of general practitioners: an analysis of initial prescriptions in general practice
British Journal of General Practice 1991; 41:244-248
HSL4237
Ãœstel I, Herxheimer A.
Progress in medicines control
Lancet 1991; 337:905-906
HSL4238
Venturelli J.
Medical ethics
Annals of the Royal College of Physicians and Surgeons of Canada 1991; 24:161-162
HSL4239
Waugh D.
Physicians’ freebies
Canadian Medical Association Journal 1991; 145:1141
HSL4240
Webber J.
Wine and cheese and CE: guidelines needed for industry sponsorship
Drug Merchandising 1991; 72:(4):33
HSL4251
Winter DL.
Consensus reports from the convinced: Manipulating the information transfer process for drug promotion [reply]
JAMA 1991; 265:(1):30
HSL4270
Kallir J.
Déja vu all over again
Medical Marketing & Media 1991; 26:(6):42
HSL4288
Re: the promotion of serrapeptase
1991
Page 20 of 23 pages ‹ First < 18 19 20 21 22 > Last ›
